Paul J Muller1, Brian C Wilson. 1. Division of Neurosurgery, St. Michael's Hospital, University of Toronto, Ontario, Canada. mullerp@smh.toronto.on.ca
Abstract
BACKGROUND AND OBJECTIVES: PDT has been used in the treatment of malignant brain tumors. This communication updates our series of unselected malignant gliomas treated with Photofrin-PDT. STUDY DESIGN AND METHODS: We examined the records of 112 patients with malignant gliomas, metastatic brain tumors and meningiomas treated with Photofrin-PDT at St. Michael's Hospital, Toronto. These patients were treated prior to the onset of ongoing randomized trials in Photofrin PDT or had pathology that excluded them from such trials. RESULTS: The overall post-PDT survival of 96 patients with supratentorial gliomas was 42 weeks, with a 40 and 22% 1- and 2-year survival, respectively. The greater the degree of oligodendroglial involvement the longer was the survival. Seventy-five percent of patients had no significant post-operative complications. CONCLUSIONS: Photofrin-PDT was safe. However, higher light doses than were used in these patients may be required for improved responses. Copyright 2006 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: PDT has been used in the treatment of malignant brain tumors. This communication updates our series of unselected malignant gliomas treated with Photofrin-PDT. STUDY DESIGN AND METHODS: We examined the records of 112 patients with malignant gliomas, metastatic brain tumors and meningiomas treated with Photofrin-PDT at St. Michael's Hospital, Toronto. These patients were treated prior to the onset of ongoing randomized trials in Photofrin PDT or had pathology that excluded them from such trials. RESULTS: The overall post-PDT survival of 96 patients with supratentorial gliomas was 42 weeks, with a 40 and 22% 1- and 2-year survival, respectively. The greater the degree of oligodendroglial involvement the longer was the survival. Seventy-five percent of patients had no significant post-operative complications. CONCLUSIONS: Photofrin-PDT was safe. However, higher light doses than were used in these patients may be required for improved responses. Copyright 2006 Wiley-Liss, Inc.
Authors: Zheng Huang; Qun Chen; Kenneth C Dole; Al B Barqawi; Yang K Chen; Dominique Blanc; Brian C Wilson; Fred W Hetzel Journal: Photochem Photobiol Sci Date: 2007-08-22 Impact factor: 3.982
Authors: Pramod V Butte; Adam N Mamelak; Miriam Nuno; Serguei I Bannykh; Keith L Black; Laura Marcu Journal: Neuroimage Date: 2010-11-03 Impact factor: 6.556
Authors: Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab Journal: CA Cancer J Clin Date: 2011-05-26 Impact factor: 508.702
Authors: Ronald J Bernardi; Amanda R Lowery; Patrick A Thompson; Susan M Blaney; Jennifer L West Journal: J Neurooncol Date: 2007-09-06 Impact factor: 4.130
Authors: Y Fujita; T Sasayama; K Tanaka; K Kyotani; H Nagashima; M Kohta; H Kimura; A Fujita; E Kohmura Journal: AJNR Am J Neuroradiol Date: 2019-11-21 Impact factor: 3.825
Authors: Zheng Huang; Heping Xu; Arlen D Meyers; Ali I Musani; Luowei Wang; Randall Tagg; Al B Barqawi; Yang K Chen Journal: Technol Cancer Res Treat Date: 2008-08